CorMedix Inc. (CRMD) stock

CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 15/3087% below fair value

$4.66−0.18 (-3.72%)

Close on Nov 13, 2026Market cap $363.22MP/E –Yield –

CorMedix EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

CorMedix's EV/EBITDA was 0.7× on Nov 11, 2026, against 6.9× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.7×	−7.5
2025	Dec 31, 2025	8.2×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CRMD.

Revenue growth92.5% · median 38.4%

Gross margin77.5% · median 84.0%

Operating margin38.6% · median -9.3%

Net margin15.5% · median -15.1%

Advertisement
300 × 250

See a number that looks wrong?